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Abstract
Purpose Idazoxan hydrochloride (IDA) is a 241 molecu-
lar weight imidazoline and adrenoreceptor ligand. It binds
to mitochondrial membranes and promotes apoptosis of
pancreatic beta cells. Since IDA has not been tested against
tumor cells, the purpose of our study was to determine if
IDA has antineoplastic activity.
Methods We used the conversion of a soluble tetrazolium
salt to an insoluble formazan precipitate and diVerential
staining cytotoxicity assays to determine if IDA was cyto-
toxic to cell lines of murine lung cancer and human prostate
cancer, as well as to a variety of fresh human tumor sam-
ples. We used Xow cytometry to analyze cell death and cal-
reticulin expression.
Results IDA is cytotoxic to both cell lines and against ali-
quots of specimens of breast, gastric, lung, ovarian and
prostate cancers as well as non-Hodgkin’s lymphoma. It
produces apoptotic cell death and promotes calreticulin
expression, suggesting that IDA might be immunomodula-
tory in vivo.
Conclusion We anticipate that IDA will be clinically use-
ful in cancer treatment.
Keywords Idazoxan · Imidazoline receptor · 
Calreticulin · Apoptosis · Human tumors
Introduction
Imidazoline compounds elicit diverse eVects on cell growth
and death. At least three subtypes of imidazoline receptors
have been described: I1, I2 and I3 [1–3]. These are diVeren-
tially expressed on a variety of tissues, I1 on brain, kidney,
and heart, I2 on brain, kidney, liver, and adipose tissue, and
I3 on pancreatic beta cells. Each has putative endogenous
ligands and a variety of exogenous ligands which can inXu-
ence sympathetic control, monoamine turnover, and insulin
secretion [4].
In contrast, some imidazoles protect cerebellar granule
cells against glutamate-induced toxicity independently of
imidazoline receptors [5]. Nutlin, synthesized by Vassielev
et al. [6], binds to HDM2 protein inhibiting its interaction
with P53 [7]. And other imidazoles inhibit the growth of
pancreatic beta cells by unknown mechanisms [8]. These
compounds interact with distinct plasma membrane sites
termed imidazoline or non-adrenergic imidazoline prefer-
ring binding sites [4]. These sites are also concentrated on
outer mitochondrial membranes [9, 10].
IDA, a benzodioxane-imidazoline analog has high aYn-
ity for mitochondrial binding [9]. Examination of the pro-
Wle of cellular DNA in idazoxan-treated immortalized
beta cells revealed that the drug induced an increase in
DNA fragmentation within only a few hours of exposure,
suggesting the induction of apoptosis [11]. In addition, an
increased number of BRIN-BD11 pancreatic beta cells
showed positive surface staining with annexin-V after
exposure to IDA for 12 h (H. Gao and N.G. Morgan, per-
sonal communication).
Since studies of apoptosis induction with imidazoles
have been performed in pancreatic beta cells, we investi-
gated the potential of IDA to promote apoptotic death in
tumor cell lines and fresh human tumor samples.
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Lewis lung carcinoma cells (3LL), kindly provided by Dr.
V. Pollack (PWzer, Groton, CT, USA), were stored in liquid
nitrogen. They were grown in RPMI-1640 medium supple-
mented with 10% fetal bovine serum (FBS), 0.05 mg/ml
gentamicin and 2 mM glutamine (FBS medium at 37°C in
an atmosphere containing 5% CO2 and passaged by mono-
layer culture. The cells were harvested from exponentially
growing cultures between passage 5 and 20.
DU-145 human prostate cancer was obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA). The cells were cultured in DMEM (GIBCO/BRL
Life Technologies, Grand Island, NY, USA) supplemented
with 10% deWned fetal bovine serum (FBS) (HyClone,
Logan, UT, USA) and 0.5 g/ml gentamicin (Sigma Chem-
icals, St. Louis, MO, USA). Cells were incubated at 37°C
in the dark in a humidiWed atmosphere. All testing was
done on cells that were in passage 3–12.
Reagents
IDA salt was purchased from Sigma-Aldrich Corp (St.
Louis, MO, USA).
Assays
The MTT assay is based on the conversion of a soluble tet-
razolium salt [3-(4.5 dimethylthiazol2-yl)-2.5 diphenyltet-
razolium bromide, (MTT)] to an insoluble formazan
precipitate by living cells [12]. Cells to be tested were har-
vested during log phase growth as previously described
[13]. After a 48-h incubation period at 37°C in 5% CO2
10 l of the drug to be tested was added. Plates were incu-
bated for 24 h at the above conditions following which
MTT (20 l, 5 mg/ml) was added to each well. Plates were
incubated for 4 h, after which the medium was removed
and the resultant formazan crystals solubilized with dime-
thyl sulfoxide. The optical density (OD) of the solution was
then measured at 540 nm using a multiscan spectrophotom-
eter. The surviving fraction was calculated using the for-
mula: mean of test sample/mean of untreated sample
(control).
Apoptotic cells were determined after 24-h exposure to
10 M etoposide or to 10–500 M IDA in standard cul-
ture conditions by cytometric staining for propidium
iodide and annexin V use of the annexin V—FITC apop-
tosis Detection Kit (BioVision Research, Mountain View,
CA, USA). Calreticulin expression was deWned using
mouse anti-calreticulin monoclonal antibody (FMC75)
Stressgen, (Ann Arbor, MI, USA) and goat anti-mouse
IgG (H + L) Hu ads FITC from Caltag Laboratories (Bur-
lingame, CA, USA).
Cells were analyzed for Xuorescence staining using a
FACSCalibur (BD Biosciences, San Jose, CA, USA) and
CelQuest software. 10,000 cells were gated by forward/side
scatter and transferred to a histogram plot. Percent positive
staining cells were determined by subtracting isotype con-
trol background.
The diVerential staining cytotoxicity (DiSC) assay was
performed as previously described on aliquots of fresh
human tumor cells isolated from lymph nodes, eVusions, or
biopsies. Specimens were most typically submitted via the
anatomic pathology laboratories of the submitting hospi-
tals, but were occasionally submitted directly from the
operating room. Solid tumor specimens (not exposed to
Wxatives or frozen) were placed in cold transport medium
(CO2-independent medium, Invitrogen/GIBCO, Grand
Island, NY, USA) supplemented with penicillin/streptomy-
cin, amphotericin B, insulin/selenium/transferring, and
10% low endotoxin, heat inactivated fetal bovine serum.
Specimens were placed in styrofoam shipping boxes, con-
taining 350 g blocks of “blue ice” frozen to ¡20°C. These
were shipped either via FedEx priority overnight delivery
service or via local land courier. Fluid specimens were
mixed well to suspend cell clusters and then poured into
sterile 500 ml polypropylene transport bottles (10–15 units
of heparin sulfate added per ml of Xuid submitted). More
than half of all specimens were submitted via FedEx and
over 90% were received either the day of biopsy or the day
following biopsy. After 96 h in polypropylene culture tubes
with and without IDA (6.7–200 ug/ml) Fast Green dye as
well as 30,000 acetaldehyde-Wxed duck red blood cells
(DRBCs), as internal control, were added. Cells excluding
Fast Green were viable and unstained, whereas “dead cells”
and DRBCs stained bright green. The slides were counter-
stained so that viable normal cells and tumor cells could be
identiWed morphologically and quantitated against the
DRBCs from which the percent of viable tumor cells were
compared between IDA containing and control cultures and
expressed as percent of control cell survival [14, 15].
Ethical standards
Cell lines and patient materials were handled in accord with
institutional guidelines and patient consent requirements. A
United States patent has been Wled by the University of
California, “Idazoxan as an anticancer agent.”
Results
IDA is cytotoxic to both 3LL and DU-145 cells as dis-
played in Fig. 1 at concentrations of 0.05–1.0 mg/ml.Cancer Chemother Pharmacol (2009) 64:1157–1163 1159
123
Figure 2 compares the induction of annexin V expression
by IDA and by etoposide, the positive control after 24-h
drug exposure resulting in 95.7 versus 93.5% apoptotic
3LL cells, respectively. Calreticulin expression due to IDA
also exceeds that achieved by etoposide in 3LL and
DU-145 cells by 90 versus 40% and 51 versus 3%, respec-
tively, although at greater IDA concentration (Fig. 3).
Table 1 displays the cytotoxic activity of IDA against 11
diVerent fresh tumor samples derived from patients with a
variety of neoplasms (the majority of which had been previ-
ously treated with the indicated chemotherapeutics) deter-
mined after 96 h of continuous exposure to 6.7–200 mcg/ml
IDA. The data points are limited by the amount of material
available per patient. However, a consistent dose response
eVect is present, which is most striking in the gastric and
breast cancer samples. In Wve specimens, there were suY-
cient numbers of readily identiWable normal cells to score
drug eVects against these normal cells. In one specimen,
IDA had no detectable eVect on normal mesothelial cells,
while reducing the survival of tumor cells (adenocarcinoma
of unknown primary) to 60% of control (tested at the 67 g/
ml concentration). The same concentration (67 g/ml)
reduced the survival of normal lymphocytes (n =3 )  a n d
normal macrophages (n = 1) to 1% of control.
Discussion
Our results show that IDA is cytotoxic to cell lines of
murine Lewis Lung cancer and human prostate cancer
DU-145 in vitro (Fig. 1). The former arose spontaneously
in a C57Bl/6 mouse as an anaplastic lung cancer. It was
used for many years in cancer drug development by the
Fig. 1 Cytotoxicity of murine Lewis Lung Cancer (3LL), (solid line)
and human prostate cancer (DU-145), (broken line) produced by IDA
after 24-h drug exposure in MTT assay
Fig. 2 Apoptosis detection by cytometric staining for Propedium io-
dide and annexin V after 24-h exposure to 500 M IDA compared to
10 M etoposide (positive control) 95.7 versus 93.5%1160 Cancer Chemother Pharmacol (2009) 64:1157–1163
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National Cancer Institute, and was found to be the most
refractory murine tumor in the screening program for eVec-
tive chemotherapeutic agents [16, 17].
IDA is also cytotoxic to a variety of fresh human tumor
samples in vitro (Table 1). At the highest IDA concentra-
tion tested, 200 mcg/ml, only 1% of the cells of the Wve
tumor specimens tested remained viable, but the deepest
dose responses occurred in untreated gastric cancer and
previously treated breast and prostate cancer specimens.
Previously treated non-Hodgkin’s lymphoma, and an
ovarian cancer as well as an untreated poorly diVerenti-
ated tumor of unknown primary site were the most
sensitive tumors. Whereas a previously treated ovarian
tumor as well as previously treated colon cancer and
adenocarcinoma of unknown primary site specimens were
relatively resistant.
The ability to predict in vivo responses of patients from
in vitro chemosensitivity testing of their tumors has been
intensively studied. The DiSC assay is one of a class of
fresh tumor, primary culture assays measuring cell death as
an endpoint. Other assays of this class include the MTT
assay, ATP assay, and Xuorescein diacetate assay. The
above four assays have been compared with each other and
have been found to give similar results in fresh tumor spec-
imens in cases where more than 70% of the viable cells
present are tumor cells [18]. The major advantage of the
DiSC assay is that it provides the cell death endpoint which
is most speciWc for drug eVects on tumor cells, in a mixed
Fig. 3 Calreticulin expression 
of apoptotic cells induced by 
exposure to 10 M etoposide 
(positive control broken line) 
compared to 500 M IDA, (solid 
line) at 24 h: 3LL 40 versus 
90%, DU-145 3 versus 51%Cancer Chemother Pharmacol (2009) 64:1157–1163 1161
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population of tumor and normal cells. Cell death endpoints
have been consistently found to predict for both patient
response to chemotherapy and for patient survival with che-
motherapy, in 40 published studies in more than 2,000
patients [19]. Therefore, the DiSC assay results reported in
Table 1 suggest that IDA will prove to be an eVective clini-
cal chemotherapeutic agent.
There is a considerable clinical experience with the use
of IDA. During the 1980s and 1990s IDA was studied in
patients with a variety of neuropsychiatric disorders,
including Alzheimer’s dementia, bipolar depression,
schizophrenia, supranuclear palsy, and Parkinson’s disease
[20–24]. IDA dosing could be tolerated at 240 mg daily
with minimal side eVects of nausea and asymptomatic
decline in standing diastolic blood pressure [21]. No pan-
creatic toxicities were described in the use of IDA in neuro-
psychiatric patients. However, since the maximum
tolerated dose of IDA has not been deWned, a Phase I trial
would be required before speciWc trials of drug eYcacy
could be carried out in patients with malignancies.
Many eVective chemotherapeutic drugs produce tumor
apoptosis [25]. Flow cytometric analysis using annexin V
expression shows that 96% of 3LL cells become apoptotic
after 24-h exposure to IDA. Recent studies have shown that
some, but not all, apoptotic promoting chemotherapeutic
drugs enhance membrane expression of calreticulin, the
cytoplasmic chaperone protein. Since it is appreciated that
calreticulin expressing apoptotic tumor cells are frequently
immunogenic and are recognized by the host immune sys-
tem leading to tumor rejection [26, 27], we deWned calreti-
culin expression by 3LL and DU-145 cells after exposure to
IDA. Ninety percent of 3LL cells and 40% of DU-145 cells
overexpress calreticulin after 24-h incubation with IDA
from baselines of less than 3 and 9%, respectively.
Since chemotherapeutic agents kill tumors by Wrst-order
kinetics, it has been suggested that tumor cure depends on
the host immune response to eradicate residual viable
tumor [28–30]. Recent observation regarding chemothera-
peutically induced calreticulin overexpression by apoptotic
tumor cells support this concept [26, 27]. The ability of
IDA to produce calreticulin overexpression in 3LL and
DU-145 suggest that it might promote immune recognition
and rejection of syngeneic tumors by an intact host.
Etoposide is an immunosuppressive topoisomerase II
inhibiting drug that is widely used clinically to treat a vari-
ety of tumors, including leukemia, lymphoma, lung, and
testicular cancer [31]. It impairs the integrity of DNA
strand replication, promotes apoptosis and is used as a posi-
tive control for calreticulin expression induction [25, 32].
We have previously shown that etoposide produces impor-
tant immune activating eVects in vivo leading to rejection
of murine models of leukemia and lung cancer [33, 34].
Mice bearing L1210 acute lymphatic leukemia which had
achieved a sustained response to etoposide rejected a subse-
quent L1210 challenge [33]. This eVect is tumor speciWc
and mediated by CD8-T lymphocytes [35]. We have also
shown that mice bearing 3LL eVectively treated with etopo-
side behave similarly. In addition, the majority of naïve
mice that had survived an inoculation of viable 3LL cell,
which had previously been incubated in vitro with etopo-
side rejected challenge with wild type 3LL [34].
Although the biochemical mechanism by which IDA
promotes tumor cell death is not known, our work shows
that IDA has antineoplastic activity in vitro and its cyto-
toxic eVect is produced apoptotically. This eVect is associ-
ated with a marked induction of calreticulin membrane
expression, suggesting that in addition to its potential
development as a cytotoxic antineoplastic agent, IDA may
Table 1 Idazoxan cytotoxicity against aliquots of fresh human tumor samples by DiSC assay expressed as percent viability compared to control
bev bevacizumab; bor bortezomib; cap capecitabine; car carboplatin; cis cisplatin; cyt cyclophosphamide; doc docetaxel; dox doxorubicin; dxl
doxil; X Xudarabine; fu 5-Xuorouracil; gem gemcitabine; leu leukovorin; onc vincristine; oxa oxaliplatin; pac paclitaxel; prd prednisone; rit ritux-
imab
Tumor Prior therapy Idazoxan concentration (mcg/ml)
6.7 20 67 200
Adenocarcinoma unknown primary gem, oxa; cis, cap 100 60
Breast cyt, dox; pac 70 1
Colon cap, oxa 74 52
Gastric None 75 2
NHL (diVuse mixed large/small cell) X, rit 100 23 1 1
NHL (mantle cell) cyt, dox, onc, pred, rit; bor, gem, cyt 91 35 1 1
Non-small cell lung gem, cis; fu, leu 1 1
Ovarian car, pac; bev 97 100
Ovarian car, pac; gem, dxl 80 30 3 1
Poorly diVerentiated unknown primary None 28 2
Prostate doc 85 80 15 11162 Cancer Chemother Pharmacol (2009) 64:1157–1163
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also prove useful in initiating host immunologic responses
against autologous tumors. In vivo studies exploring these
possibilities are underway. Our preliminary results in this
area are encouraging since we have observed a 50% reduc-
tion in the growth of 3LL tumor in mice treated with IDA,
and delay in the growth of wild type 3LL cells in syngeneic
host mice previously inoculated with calreticulin express-
ing 3LL cells conditioned in vitro with IDA.
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